Your browser doesn't support javascript.
loading
MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.
Lee, Jen-Chieh; Liu, Shu; Wang, Yucheng; Liang, You; Jablons, David M.
Affiliation
  • Lee JC; Thoracic Oncology, Department of Medicine, University of California, San Francisco, CA 94143, USA.
  • Liu S; Touro University, College of Osteopathic Medicine, Vallejo, CA 94592, USA.
  • Wang Y; Thoracic Oncology, Department of Medicine, University of California, San Francisco, CA 94143, USA.
  • Liang Y; Thoracic Oncology, Department of Medicine, University of California, San Francisco, CA 94143, USA.
  • Jablons DM; Thoracic Oncology, Department of Medicine, University of California, San Francisco, CA 94143, USA.
Oncotarget ; 13: 1217-1236, 2022 Nov 02.
Article in En | MEDLINE | ID: mdl-36342456
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Protein Kinase Inhibitors / STAT Transcription Factors / Cyclin-Dependent Kinase 8 Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Oncotarget Year: 2022 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Protein Kinase Inhibitors / STAT Transcription Factors / Cyclin-Dependent Kinase 8 Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Oncotarget Year: 2022 Document type: Article Affiliation country: